Evidence map›Paper›PMID 33370279›Full record

ArticlePLoS genetics2020

Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum.

Aabha I Sharma, Sara H Shin, Selina Bopp, Sarah K Volkman, Daniel L Hartl, Dyann F Wirth

Abstract read
In one paragraph

Article in PLoS genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Global assessment of partial artemisinin resistance: multicenter trial across Kenya, Peru, and Thailand in patients with uncomplicated Plasmodium falciparum malaria.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Article
  7. Artemisinin-resistant malaria.Clinical microbiology reviews · 2024
    Review
  8. Article
  9. Article
  10. Detection of novelFrontiers in cellular and infection microbiology · 2024
    Article
  11. Antimicrobial agents and chemotherapy · 2023
    Article
  12. Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Prevalence of Mutations in thePharmaceutics · 2021
    Article
  19. Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.International journal for parasitology. Drugs and drug resistance · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aabha I SharmaDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.ORCID 0000-0003-0209-5608
Sara H ShinDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.
Selina BoppDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.ORCID 0000-0002-9412-9766
Sarah K VolkmanDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.
Daniel L HartlDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.ORCID 0000-0002-0302-306X
Dyann F WirthDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.ORCID 0000-0002-8604-4455

Funding

Novel Genetic Mechanism of Artemisinin Resistance for MalariaR01AI099105 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HARTL, DANIEL L, WIRTH, DYANN F · 2013 to 2021
$5.4M
NIAID NIH HHS R01 AI099105
6 · The paper itself

Abstract

Malaria continues to impose a significant health burden in the continent of Africa with 213 million cases in 2018 alone, representing 93% of cases worldwide. Because of high transmission of malaria within the continent, the selection pressures to develop drug resistance in African parasites are distinct compared to the rest of the world. In light of the spread of resistance to artemisinin conferred by the C580Y mutation in the PfKelch13 propeller domain in Southeast Asia, and its independent emergence in South America, it is important to study genetic determinants of resistance in the African context using African parasites. Through in vitro evolution of Senegalese parasites, we had previously generated the artemisinin-resistant parasites Pikine_R and Thiès_R and established pfcoronin mutations to be sufficient to confer artemisinin resistance in the standard ring-stage survival assay (RSA). In the current study, we used genetic analysis of revertants to demonstrate pfcoronin to be the major driver of elevated RSA in the artemisinin-resistant parasites Pikine_R and Thiès_R evolved in vitro. We interrogated the role of a second gene PF3D7_1433800, which also had mutations in both the Pikine_R and Thiès_R selected lines, but found no evidence of a contribution to reduced susceptibility in the RSA survival assay. Nevertheless, our genetic analysis demonstrates that parasite genetic background is important in the level of pfcoronin mediated RSA survival, and therefore we cannot rule out a role for PF3D7_1433800 in other genetic backgrounds. Finally, we tested the potential synergy between the mutations of pfcoronin and pfkelch13 through the generation of single and double mutants in the Pikine genetic background and found that the contribution of pfcoronin to reduced susceptibility is masked by the presence of pfkelch13. This phenomenon was also observed in the 3D7 background, suggesting that pfcoronin may mediate its effects via the same pathway as pfkelch13. Investigating the biology of proteins containing the beta-propeller domain could further elucidate the different pathways that the parasite could use to attain resistance.

Indexed as

Drug ResistanceGenetic BackgroundMutationAntimalarialsArtemisininsKelch RepeatMicrofilament ProteinsPlasmodium falciparumProtozoan ProteinsAntimalarialsartemisininArtemisininscoronin proteinsMicrofilament ProteinsProtozoan Proteins

Identifiers

PMID33370279
PMCPMC7793257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.